摘要：目的探讨干扰素联合肝动脉栓塞化疗预防肝细胞癌根治性切除术后复发的临床价值。方法10例肝细胞癌患者于根治性切除术后2～8周经肝动脉导管行栓塞化疗。化疗后皮下注射重组α干扰素2a(罗扰素)，第1～4周自100万单位渐增至450万单位维持12周。每周3次，4～6周后重复栓塞化疗一次。结果9例患者随访超过1年，1例9个月，所有患者均未见肝内复发。结论罗扰素可能有助于减少肝癌根治性切除术后肝内复发。

Preliminary study on the role of Roferon-A (Interferon α2a) combined with postoperative arterial chemoembolization in the prevention of recurrence after curative resection for human hepatoceilular carcinoma

QIU Shuangjian ,YE Sheng-long ,TANG Zhaoyou,et al.

(Liver Cancer Institute,Shanghai Medical University,Shanghai 200032)

Abstract：Objective To evaluate the role of Roferon-A (interferon α-2a) combined with postoperative arterial chemoembolization in the prevention of recurrence after curative resection for HCC.Methods Postoperative arterial chemoem-bolization via a total implanted port system through the hepatic artery,followed by Roferon-A injection subcutaneously on the next day.This was given to ten patients in 2～8 weeks after curative resection.Interferon α2a (Rcferon-A) was given after hemoembolization as follows:the dosages were increased gradually from 1.0 MU three times weekly (t.I.w.) in the 1st week to 4.5 MU in the 4th week and maintained till 12th week.Chemocmbolization was repeated 4～6 weeks after the first course of chemoembolization.Results Among these patients,nine patients had been followed up for more than 12 months and one patient followed up for nine months and no intrahepatic recurrences were found.Conclusion Roferon-A may be helpful for re-ducing the intrahepatic recurrence after curative resection for HCC.

Keywords：Interferon;Hepatocellular carcinoma,primary;Chemoembolication

基金项目：本课题受“九五”国家医学科技攻关项目(96-906-01-20)部分资助。

参考文献：

［1］Tang ZY,Yu YQ,Zhou XD.An important approach to prolonging survival further after radical resection of AFP positive hepatocellular arcinoma.J Exp Clin Cancer Res,1984,3:359-368.

［2］Ikeda K,Saitoh S,Su2uki Y,et al.Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus——a pilot study.Cancer,1998,82:827-835.

［3］Nishiguchi S,Kuroki T,Nakatani S,et al.Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.Lancet,1995,346:1051-1055.

［4］Gutterman JU.Cytokine therapeutics:lessons from interferon-α.Proc Natl Acad Sci USA,1994,91:1198-1205.

［5］Singh RK,Gutman M,Bueana CD,et al.Interferon-α and-β down-regulate the expression of basic fibroblast growth factor in human carci-nomas.Proc Nad Acad Sci USA,1995,92:4562-4566.

［6］Sidky YA,Borden EC.Inhibition of angiogenesis by interferon:effects on tumor and lymphocyte-induced vascular responses.Cancer Res,1987,47:5155-5161.

［7］Dvorak HF,Gresser I.Microvascu[ar injury in pathogenesis of interfe-ron-induced necrosis of subcutaneous tumors in mice.J Natl Cancer In-st,1989,81:497-502.

［8］Kong HL,Crystal RG.Gene therapy strategies for tumor antiangio-genesis.J Natl Cancer Inst,1998,90:273-286.

收稿日期：1999-11-01